Future Medicine
Monday, June 03, 2024
Company Presentation
Metabolic Diseases
Company Presentation Theater 2
Future Medicine (hereinafter referred to as "we") is a bio-venture, focusing on nucleoside-based drug development company. we directly synthesize new drug candidates based on the nucleoside compound library of “FOCUS” (Futuremedicine Origin Compound Library Universal System), a self-built synthetic material derivation platform for drug development, and research and develop new drugs that can treat target diseases by regulating various in vivo targets involving nucleoside. In particular, we are promoting research and commercialization of new drugs for intractable diseases for which there are no treatments in the global market through new drug candidates such as metabolic diseases, anticancer drugs, and antiviral drugs, which are the main pipeline.
We are expanding our pipelines with metabolic disease such as NASH and obesity, also innovative compounds for oncology area. From our FOCUS, we directly synthesizes and derive various new drug candidates for next pipelines.
Company Website:
http://www.futuremedicine.co.kr
Lead Product in Development:
FM101
Lead asset, FM101, is a nucleoside drug that is an antagonist of A3 adenosine receptor (A3AR), and we are developing it as a treatment for non-alcoholic steatohepatitis (NASH), a metabolic disease, as its anti-inflammatory and anti-fibrotic effects have been confirmed through initial studies. currently phase 2a clinical trial is ongoing.
FM801
FM801 burns fat by converting energy-storing white fat to brown fat through modulation of adenosine receptors in the body, which we believe may have therapeutic benefits for obesity and associated metabolic diseases. Our nonclinical results demonstrated equivalent weight loss by fat burning without muscle loss compared to existing GLP-1 analogs, and maintenance of weight loss without regain when the drug is discontinued. We also expect no gastrointestinal or psychiatric side effects, which we published in the International Journal of Obesity (2022) 462128-2136.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Exchange
KRX - KONEX
Ticker
A341170
Company HQ City
Seongnam
Company HQ State
Kyoenggi
Company HQ Country
Korea, Republic of
CEO/Top Company Official
Wanseok Jeong, MBA
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())